New dosing strategy aims to fight lung Cancer's spread to the brain
NCT ID NCT07348965
Summary
This study is testing if giving a higher dose of the lung cancer drug furmonertinib every other day is more effective and safe for patients whose cancer has spread to the lining of the brain and spinal cord. It will enroll 42 adults with a specific genetic mutation (EGFR) whose cancer worsened after initial treatment. Researchers want to see if this schedule gets more drug into the spinal fluid to better control the cancer there and improve how long patients live without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Hospital of Chinese Medicine
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.